34. Neurofibromatosis Clinical trials / Disease details

Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

7 trials found

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000156-35-NL (EUCTR)	18/03/2021	03/03/2020	89Zr-BevacizumabPET/CT imaging of vestibular schwannomas for the prediction of bevacizumabtreatment ...	89Zr-BevacizumabPET/CT imaging of vestibular schwannomas for the prediction of bevacizumabtreatment ...	Neurofibromatosis type 2;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: 89Zr-bevacizumab INN or Proposed INN: Unknown Other descriptive name: BEVACIZUMAB ZIRCONI ...	Leiden University Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 2	Netherlands
2	JPRN-JapicCTI-194999	15/10/2019	14/10/2019	BeatNF2 trial	A Randomized Double-blind Multicenter trial to Assess the Efficacy and Safety of Bevacizumabfor Neur ...	Neurofibromatosis type 2	Intervention name : Bevacizumab (Genitical Recombination) INN of the intervention : Bevacizumab (Geniti ...	Kiyoshi Saito	Masazumi Fujii, Masao Kobayakawa, Akihiro Inano, Jun Sakuma, Taku Sato, Akio Morita, Mitsuhiro Haseg ...	pending	18	64	BOTH	60	Phase 2	Japan
3	ChiCTR1800016040	2018-05-09	2018-05-08	Clinical efficacy of Bevacizumab in the treatment of Type II Neurofibromatosis	Clinical efficacy of Bevacizumab in the treatment of Type II Neurofibromatosis	Type II Neurofibromatosis	Case series:Bevacizumab therapy;	Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University, School of Medicine	NULL	Recruiting	6		Both	Case series:30;		China
4	NCT01767792 (ClinicalTrials.gov)	May 15, 2013	7/1/2013	Phase 2 Study of Bevacizumabin Children and Young Adults With NF 2 and Progressive Vestibular Schwan ...	Open-label, Phase 2 Study of Bevacizumabin Children and Young Adults With Neurofibromatosis 2 and Pr ...	Neurofibromatosis Type 2;Progressive Vestibular Schwannomas	Drug: Bevacizumab	University of Alabama at Birmingham	Genentech, Inc.	Active, not recruiting	6 Years	N/A	All	22	Phase 2	United States
5	NCT01661283 (ClinicalTrials.gov)	September 2012	7/8/2012	SARC016: Study of Everolimus With Bevacizumabto Treat Refractory Malignant Peripheral Nerve Sheath T ...	Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumabin Patients With Spora ...	Malignant Peripheral Nerve Sheath Tumors;MPNST;Sarcoma	Drug: everolimus;Drug: bevacizumab	Sarcoma Alliance for Research through Collaboration	Novartis Pharmaceuticals;Genentech, Inc.;United States Department of Defense	Completed	18 Years	N/A	All	25	Phase 2	United States
6	NCT01207687 (ClinicalTrials.gov)	October 2010	1/9/2010	Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)	Phase 2 Study of Bevacizumabin Children and Adults With Neurofibromatosis Type 2 and Symptomatic Ves ...	Vestibular Schwannoma;Neurofibromatosis Type 2	Biological: bevacizumab;Other: laboratory biomarker analysis;Procedure: quality-of-life assessment	National Cancer Institute (NCI)	NULL	Completed	12 Years	N/A	All	14	Phase 2	United States
7	NCT01125046 (ClinicalTrials.gov)	July 2010	7/5/2010	Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas	Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas	Acoustic Schwannoma;Adult Anaplastic Meningioma;Adult Ependymoma;Adult Grade I Meningioma;Adult Grad ...	Biological: bevacizumab	Northwestern University	NULL	Unknown status	18 Years	N/A	All	50	Phase 2	United States

First Previous1Next Last